Lisata Therapeutics (LSTA) Competitors $2.82 -0.11 (-3.75%) (As of 02:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends LSTA vs. KFFB, NEOS, ORMP, NVCT, ANVS, QNCX, CABA, ASRT, GBIO, and PWUPShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Kentucky First Federal Bancorp (KFFB), Neos Therapeutics (NEOS), Oramed Pharmaceuticals (ORMP), Nuvectis Pharma (NVCT), Annovis Bio (ANVS), Quince Therapeutics (QNCX), Cabaletta Bio (CABA), Assertio (ASRT), Generation Bio (GBIO), and PowerUp Acquisition (PWUP). Lisata Therapeutics vs. Kentucky First Federal Bancorp Neos Therapeutics Oramed Pharmaceuticals Nuvectis Pharma Annovis Bio Quince Therapeutics Cabaletta Bio Assertio Generation Bio PowerUp Acquisition Kentucky First Federal Bancorp (NASDAQ:KFFB) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, community ranking and risk. Does the MarketBeat Community favor KFFB or LSTA? Kentucky First Federal Bancorp received 71 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 92.86% of users gave Lisata Therapeutics an outperform vote while only 60.00% of users gave Kentucky First Federal Bancorp an outperform vote. CompanyUnderperformOutperformKentucky First Federal BancorpOutperform Votes8460.00% Underperform Votes5640.00% Lisata TherapeuticsOutperform Votes1392.86% Underperform Votes17.14% Which has more volatility and risk, KFFB or LSTA? Kentucky First Federal Bancorp has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Is KFFB or LSTA more profitable? Lisata Therapeutics has a net margin of 0.00% compared to Kentucky First Federal Bancorp's net margin of -8.93%. Kentucky First Federal Bancorp's return on equity of -1.26% beat Lisata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kentucky First Federal Bancorp-8.93% -1.26% -0.17% Lisata Therapeutics N/A -51.19%-45.16% Does the media refer more to KFFB or LSTA? In the previous week, Lisata Therapeutics had 5 more articles in the media than Kentucky First Federal Bancorp. MarketBeat recorded 6 mentions for Lisata Therapeutics and 1 mentions for Kentucky First Federal Bancorp. Lisata Therapeutics' average media sentiment score of 1.00 beat Kentucky First Federal Bancorp's score of 0.98 indicating that Lisata Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kentucky First Federal Bancorp 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lisata Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in KFFB or LSTA? 3.2% of Kentucky First Federal Bancorp shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 3.9% of Kentucky First Federal Bancorp shares are owned by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable valuation and earnings, KFFB or LSTA? Kentucky First Federal Bancorp has higher revenue and earnings than Lisata Therapeutics. Kentucky First Federal Bancorp is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKentucky First Federal Bancorp$16.53M1.29-$1.72M-$0.19-13.89Lisata TherapeuticsN/AN/A-$20.84M-$2.51-1.12 Do analysts recommend KFFB or LSTA? Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 431.91%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than Kentucky First Federal Bancorp.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kentucky First Federal Bancorp 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryLisata Therapeutics beats Kentucky First Federal Bancorp on 11 of the 17 factors compared between the two stocks. Ad Darwin2024 Election Year Stocks: Uncover Hidden Gems!In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.Secure your copy now by clicking this link. Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.66M$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-1.125.5695.6214.26Price / SalesN/A371.591,217.1987.73Price / CashN/A52.5939.5936.27Price / Book0.7110.236.946.36Net Income-$20.84M$153.22M$118.89M$225.56M7 Day Performance0.36%-1.36%-1.33%-0.10%1 Month Performance-5.37%-6.81%-3.17%2.02%1 Year Performance29.95%32.27%32.49%27.87% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics3.3126 of 5 stars$2.82-3.8%$15.00+431.9%+33.6%$23.66MN/A-1.1230Analyst ForecastKFFBKentucky First Federal Bancorp0.4532 of 5 stars$2.64+1.5%N/A-47.3%$21.36M$16.53M0.0060NEOSNeos TherapeuticsN/A$1.15flatN/A+0.0%$57.22M$64.65M-3.38213Analyst ForecastHigh Trading VolumeORMPOramed Pharmaceuticals1.478 of 5 stars$2.34+3.5%N/A+4.6%$94.33M$1.34M4.4310News CoverageNVCTNuvectis Pharma3.3184 of 5 stars$4.86-4.1%$21.00+332.1%-38.8%$93.90MN/A-4.118ANVSAnnovis Bio1.8748 of 5 stars$6.78+3.7%$32.17+374.4%+8.1%$93.56MN/A0.003QNCXQuince Therapeutics2.508 of 5 stars$2.09+13.7%$8.50+306.3%+109.1%$92.05MN/A0.0060CABACabaletta Bio2.0358 of 5 stars$1.88-16.8%$27.30+1,352.1%-87.4%$91.89MN/A-0.9550Analyst ForecastHigh Trading VolumeASRTAssertio3.2047 of 5 stars$0.95flat$3.25+242.1%-23.4%$90.71M$152.07M-1.3020Positive NewsGBIOGeneration Bio3.3756 of 5 stars$1.34-0.7%$7.50+459.7%+7.1%$89.50M$5.90M0.00150Gap UpPWUPPowerUp AcquisitionN/A$11.50flatN/AN/A$89.36MN/A0.00N/A Related Companies and Tools Related Companies Kentucky First Federal Bancorp Competitors Neos Therapeutics Competitors Oramed Pharmaceuticals Competitors Nuvectis Pharma Competitors Annovis Bio Competitors Quince Therapeutics Competitors Cabaletta Bio Competitors Assertio Competitors Generation Bio Competitors PowerUp Acquisition Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LSTA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
